Physician profile
Bill A Webb
NPI 1952364614
$3,858.96
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $1,455 · 2021: $818 · 2022: $27.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $470.55 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $372.33 | 2019-2020 | |
| Allergan, INC. | $349.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $285.95 | 2019-2020 | |
| Lilly USA, LLC | $249.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.37 | 2019-2021 | |
| Abbvie INC. | $203.01 | 2020-2022 | |
| Glaxosmithkline, LLC. | $190.38 | 2019-2020 | |
| Pfizer INC. | $175.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $139.91 | 2019-2021 | |
| Astellas Pharma US INC | $138.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.72 | 2019-2021 | |
| Novo Nordisk INC | $118.38 | 2019-2021 | |
| Daiichi Sankyo INC. | $103.76 | 2019-2021 | |
| Amarin Pharma, INC. | $97.94 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.94 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $85.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $64.99 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $64.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.19 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $57.71 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $53.07 | 2019 | |
| Indivior INC. | $49.13 | 2020-2021 | |
| Genentech USA, INC. | $29.17 | 2019 | |
| Scilex Pharmaceuticals INC. | $20.79 | 2019 | |
| Redhill Biopharma INC. | $12.79 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.